Filing Analysis
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of the company's financial performance and operational updates via a press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2026.
- Filing date: August 10, 2026.
- The filing incorporates Exhibit 99.1 (Press Release) by reference.
Enanta Pharmaceuticals entered into an Open Market Sale Agreement with Jefferies LLC to facilitate the 'at-the-market' (ATM) offering of common stock. The company intends to sell up to $75,000,000 worth of shares through this agreement.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $75M equity issuance capacity.
- ATM offerings are often used by micro/mid-cap biotech companies to bolster cash runways, which can signal upcoming capital needs.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on July 2, 2026.
- The offering is part of a previously filed and effective Form S-3 shelf registration (No. 333-293390) dated February 11, 2026.
- Aggregate offering price limit is up to $75,000,000.
- Jefferies LLC will receive a commission of up to 3.0% of the gross sales price per share.
- Sales will be conducted via 'at-the-market' methods on Nasdaq or other existing markets.
Enanta Pharmaceuticals announced its financial results for the fiscal quarter and year ended September 30, 2025. The filing serves as a formal mechanism to furnish the company's press release containing these results via Exhibit 99.1.
📋 Key Facts
- Reporting period: Fiscal quarter and year ended September 30, 2025.
- Filing date: November 17, 2025.
- The filing incorporates a press release (Exhibit 99.1) by reference.
Enanta Pharmaceuticals announced a public offering of 6,500,000 shares of common stock at $10.00 per share. The company expects to receive approximately $60.6 million in net proceeds from the transaction.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new common stock.
📋 Key Facts
- Offering size: 6,500,000 shares of common stock.
- Offering price: $10.00 per share.
- Expected net proceeds: Approximately $60.6 million (after discounts and expenses).
- Underwriters: J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C.
- Over-allotment option: Underwriters have an option to purchase up to 975,000 additional shares.
- Expected closing date: October 2, 2025.
- Registration method: Pursuant to a shelf registration statement on Form S-3.
Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. The company provided a presentation detailing these results via Exhibit 99.1.
📋 Key Facts
- Announcement date: September 29, 2025
- Drug candidate: Zelicapavir (formerly EDP-938)
- Indication: Respiratory syncytial virus (RSV) in high-risk adults
- Study Phase: Phase 2b topline results reported as positive
- The disclosure is furnished under Item 7.01 and not filed for liability purposes.
Enanta Pharmaceuticals announced positive topline Phase 2b data for zelicapavir in treating respiratory syncytial virus (RSV) in high-risk adults. The study met key secondary endpoints, including improved symptom resolution and viral load reduction, though it did not meet the primary endpoint of time to resolution of lower respiratory tract disease symptoms.
🚩 Red Flags
- Failure to meet the primary endpoint regarding the time to resolution of lower respiratory tract disease (LRTD) symptoms in the efficacy population.
📋 Key Facts
- Phase 2b study was a randomized, double-blind, placebo-controlled trial in non-hospitalized high-risk adults (elderly or those with CHF, COPD, or asthma).
- Study population: 186 subjects total; 175 in the efficacy population.
- Zelicapavir demonstrated a favorable safety profile; no treatment discontinuations due to adverse events.
- Met key secondary endpoints: statistically significant improvement in Patient Global Impression of Severity (PGI-S) and RiiQ™ scores in the HR3 population.
- Virology results: significantly higher proportion of undetectable viral load at end of treatment vs. placebo (23.5% vs 10.0% in efficacy population).
- Hospitalization rate was lower in zelicapavir group (1.7%) compared to placebo (5.0%).
- Failed to meet the primary endpoint: no significant effect on time to resolution of the subset of four LRTD symptoms in the efficacy population.
Enanta Pharmaceuticals has announced the appointment of interim financial leadership following a medical leave of absence by its Chief Financial and Administrative Officer, Paul J. Mellett.
🚩 Red Flags
- Sudden departure of the CFO/CAO due to medical leave creates temporary leadership vacuum in critical financial roles.
📋 Key Facts
- Paul J. Mellett (Chief Financial and Administrative Officer) is on a medical leave of absence effective August 26, 2025.
- Harry R. Trout, III (VP, Finance) has been appointed interim Principal Financial Officer.
- Kathleen S. Capps (Executive Director, Accounting & Controller) has been appointed interim Principal Accounting Officer.
- The appointments are on an interim basis until Mr. Mellett is able to resume his positions.
Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer Inc. in the Unified Patent Court (UPC) of the European Union regarding Paxlovid™. The suit seeks to determine liability for the use and sale of Pfizer's COVID-19 antiviral across 18 EU member states.
🚩 Red Flags
- High cost of intellectual property litigation mentioned in forward-looking statements.
- Risk that issued patents could be found invalid or unenforceable if challenged.
📋 Key Facts
- Filed suit against Pfizer Inc. and subsidiaries in the UPC (action number 35071/2025).
- The litigation concerns European Patent No. EP 4 051 265 ('265 Patent), which was published on August 20, 2025.
- The '265 Patent is the European counterpart to U.S. Patent No. 11,358,953 ('953 Patent).
- Enanta and Pfizer are already engaged in ongoing litigation regarding the same patent technology in the United States.
- The enforcement action targets activities in 18 EU countries participating in the UPC.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly results for the fiscal quarter ended June 30, 2025. The filing serves as a formal announcement of the company's recent financial performance via a press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025.
- Filing date: August 11, 2025.
- The filing incorporates Exhibit 99.1 (Press Release) by reference.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The filing incorporates a press release (Exhibit 99.1) by reference.
- Company is listed on the Nasdaq Global Select Market under ticker ENTA.
Enanta Pharmaceuticals, Inc. reported the results of its Annual Meeting held on March 13, 2025. Stockholders approved several proposals, including the election of directors and an amendment to increase the share pool for the 2019 Equity Incentive Plan.
📋 Key Facts
- Stockholders re-elected Mark G. Foletta and Lesley Russell as Class III directors.
- Approved an amendment to the 2019 Equity Incentive Plan to increase shares reserved for issuance by 800,000 shares (11,435,985 votes in favor).
- Approved holding advisory 'say-on-pay' votes on an annual basis.
- Ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2025.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal quarter ended December 31, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended December 31, 2024.
- Filing date: February 10, 2025.
- The filing incorporates a press release (Exhibit 99.1) by reference.
Enanta Pharmaceuticals announced positive topline data from its Phase 2 pediatric study of zelicapavir for the treatment of respiratory syncytial virus (RSV). The results demonstrated a favorable safety profile and significant antiviral activity, particularly in patients treated early after symptom onset.
🚩 Red Flags
- One serious adverse event (SAE) in the zelicapavir group (community-acquired pneumonia), though deemed not treatment-related by investigators.
- Use of exploratory symptom tools (ReSViNET and RESOLVE-P) due to lack of validated regulatory tools for pediatric RSV, which may complicate future regulatory filings.
📋 Key Facts
- Phase 2 study was randomized, double-blind, dose-ranging, placebo-controlled involving 96 patients (70 zelicapavir, 26 placebo).
- Zelicapavir demonstrated a favorable safety profile; no AEs led to treatment discontinuation or withdrawal.
- Primary efficacy: Viral load decline peaked at 0.7 log on Day 9 vs. placebo in the overall population.
- Subgroup analysis: Patients randomized within 3 days of symptom onset (40% of study) showed a viral load decline of 0.9 log at Day 3 and 1.2 log at Day 5 vs. placebo.
- Dosing selected for future use: 5 mg/kg for age ≥ 28 days to <12 months; 7.5 mg/kg for age ≥12 months to ≤36 months.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 25, 2024
- Reporting period: Fiscal quarter and year-ended September 30, 2024
- The filing incorporates a press release (Exhibit 99.1) by reference.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024.
- Filing date: August 5, 2024.
- The filing incorporates a press release (Exhibit 99.1) by reference regarding results of operations and financial condition.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- The filing serves to incorporate the company's press release via Exhibit 99.1.
Enanta Pharmaceuticals, Inc. reported the results of its Annual Meeting held on March 6, 2024. Stockholders approved an amendment to the 2019 Equity Incentive Plan and re-elected three Class II directors.
📋 Key Facts
- Stockholders approved increasing the number of shares reserved under the 2019 Equity Incentive Plan by 975,000 shares (Proposal No. 2).
- Three Class II Directors (Yujiro S. Hata, Kristine Peterson, and Terry C. Vance) were re-elected to serve until the 2027 Annual Meeting.
- The advisory 'say-on-pay' vote regarding executive compensation was approved by stockholders.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2024 fiscal year.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- Reporting period: Fiscal quarter ended December 31, 2023.
- Filing date: February 7, 2024.
- The filing incorporates a press release (Exhibit 99.1) by reference.